Detalles de la búsqueda
1.
Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer.
N Engl J Med;
378(15): 1408-1418, 2018 Apr 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-29420164
2.
Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial.
Lancet Oncol;
14(13): 1307-16, 2013 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-24211163
3.
Increased serum insulin-like growth factor-1 levels are associated with prolonged response to dasatinib-based regimens in metastatic prostate cancer.
Prostate;
73(9): 979-85, 2013 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-23371521
4.
Development of patient- and observer-reported outcome measures to assess COVID-19 signs and symptoms in children and adolescents.
J Patient Rep Outcomes;
7(1): 7, 2023 01 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-36701073
5.
Cusatuzumab plus azacitidine in newly diagnosed acute myeloid leukaemia ineligible for intensive chemotherapy (CULMINATE): part one of a randomised, phase 2, dose optimisation study.
Lancet Haematol;
10(11): e902-e912, 2023 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-37914483
6.
Dasatinib combined with docetaxel for castration-resistant prostate cancer: results from a phase 1-2 study.
Cancer;
118(1): 63-71, 2012 Jan 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-21976132
7.
Lost Labor Productivity Costs of Prostate Cancer to Patients and Their Spouses: Evidence From US National Survey Data.
J Occup Environ Med;
58(4): 351-8, 2016 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-27058474
8.
The Direct Healthcare Expenditures of Prostate Cancer by Disease Severity: Evidence from US National Survey Data.
J Health Econ Outcomes Res;
3(1): 83-96, 2015.
Artículo
en Inglés
| MEDLINE | ID: mdl-37662656
9.
Long-term use of dasatinib in patients with metastatic castration-resistant prostate cancer after receiving the combination of dasatinib and docetaxel.
Cancer Manag Res;
6: 25-30, 2013.
Artículo
en Inglés
| MEDLINE | ID: mdl-23516140
10.
Once-daily dasatinib: expansion of phase II study evaluating safety and efficacy of dasatinib in patients with metastatic castration-resistant prostate cancer.
Urology;
77(5): 1166-71, 2011 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-21539969
11.
Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer.
Clin Cancer Res;
15(23): 7421-8, 2009 Dec 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-19920114
Resultados
1 -
11
de 11
1
Próxima >
>>